Description
Indication & Scope
NuoRuiDa® is a prescription endothelin A (ETA) receptor antagonist indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.
- Mechanism: Atrasentan hydrochloride is a selective endothelin A receptor antagonist that blocks the binding of endothelin-1 to ETA receptors. By inhibiting endothelin-mediated inflammatory and fibrotic pathways in the kidney, atrasentan reduces proteinuria and helps protect renal function.
- Drug class: Selective endothelin A (ETA) receptor antagonist.
- Clinical use: Reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression.
| Generic Name | Atrasentan Hydrochloride Tablets |
| Brand Name | NuoRuiDa® |
| Ingredient | Atrasentan Hydrochloride |
| Dosage Form | Tablet |
| Package | 0.75 mg × 30 tablets/bottle |
| Conditions Treated | Primary immunoglobulin A nephropathy (IgAN) with risk of rapid disease progression |
| Taboos | Hypersensitivity to atrasentan hydrochloride or any component of the product; pregnancy; severe hepatic impairment |
| Place of origin | Switzerland / Global development by Novartis |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store in a sealed container at room temperature, protected from light and moisture. |
| Manufacturer | Novartis Pharma Schweiz AG |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20250099 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 0.75 mg orally once daily.
Time: NuoReiDa® may be administered with or without food. Tablets should be swallowed whole and should not be split, crushed, or chewed.
Instructions for use: Pregnancy testing should be performed before initiation in females of reproductive potential. Treatment should continue as clinically appropriate with monitoring of proteinuria, renal function, liver function, and fluid retention. If a dose is missed, the next dose should be taken at the regularly scheduled time without doubling the dose.
Interaction: Atrasentan is metabolized primarily through CYP pathways. Concomitant use with strong CYP3A4 inhibitors may increase atrasentan exposure and should be avoided or carefully monitored.
Side effects: Common adverse reactions include peripheral edema and anemia. Other potential risks include fluid retention, liver enzyme abnormalities, and embryo-fetal toxicity. Patients should be monitored for signs of edema, weight gain, and hepatic dysfunction.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is NuoRuiDa® used for?
NuoRuiDa® (Atrasentan Hydrochloride) is used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.
How does Atrasentan Hydrochloride work?
Atrasentan is a selective endothelin A (ETA) receptor antagonist that blocks endothelin-1 signaling, reducing kidney inflammation, fibrosis, and protein leakage.
How is NuoRuiDa® administered?
NuoRuiDa® is administered orally at a recommended dose of 0.75 mg once daily, with or without food.
Is NuoRuiDa® an immunosuppressive drug?
No. Atrasentan is a non-immunosuppressive renal protective therapy that targets the endothelin pathway rather than suppressing the immune system.
NuoReiDa® | Atrasentan Hydrochloride | IgA Nephropathy | DengYueRX
INN: Atrasentan Hydrochloride
Indications: Lower proteinuria in high‑risk IgAN adults
Dosage Form: Tablet
Strength: 0.75 mg/Tablet
